LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Exome Sequencing Provides Diagnostic Assay for Intellectual Disability

By LabMedica International staff writers
Posted on 22 Nov 2012
A molecular based diagnostic assay has been used determine whether one or more genetic mutations explain a patient's intellectual disability.

Exome sequencing, which deciphers over 21,000 protein-coding genes and not the entire human genome, can be used as a diagnostic assay to determine the genetic mutations that may elucidate why some patients suffer from significant limitations both in intellectual functioning and in adaptive behavior.

A team of scientists at Radboud University (Nijmegen, The Netherlands) performed exome sequencing of 100 patients with unexplained cognitive impairment, and uncovered 79 genes with unique de novo mutations. These de novo mutations were present in the DNA of the patients but not in that of their parents whose exomes also were sequenced.

The diagnostic interpretation revealed that 16 of the 100 mutations were causative, or pathogenic. Ten of these mutations occurred in genes already known to be involved in intellectual disability, and three X-linked maternally inherited mutations were identified. In addition, de novo mutations were uncovered in three novel candidate genes, which after follow-up were found to be more frequently mutated in patients with intellectual disability. Furthermore, disruptive de novo mutations were identified in 19 additional genes with a functional link to intellectual disability. Because 19 genes were found in only a single patient, a conclusive diagnosis based on these findings could not be made.

Joseph de Ligt, MSc, bioinformatician and PhD student in human genetics, said, “The child with a cognitive disability is often an isolated case without family history of the condition, and that intellectual disability occurs in about 1% of the population. All de novo as well as X-linked mutations identified in this study were interpreted in the context of the clinical diagnosis.” The results of this study were presented on November 8, 2012, at the American Society of Human Genetics meeting, held in San Francisco, (CA, USA).

Related Links:

Radboud University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Automated Urinalysis Solution
UN-9000
Prefilled Tubes
Prefilled 5.0ml Tubes

Channels

Clinical Chemistry

view channel
Image: The method combines ultrasonic and fluorescence techniques to track amyloid aggregation in real time (Image Credit: Shutterstock)

Blood Test Measures Amyloid Seeding Activity to Detect Alzheimer’s Disease

Early, accurate diagnosis of Alzheimer’s disease (AD) remains challenging in routine practice, despite its role as the leading cause of dementia worldwide. Confirmation typically relies on cerebrospinal... Read more

Pathology

view channel
Image: TRUECAM automatically eliminates ambiguous or uninformative regions in whole-slide pathology images, enhancing the reliability of diagnostic analysis. (Photo courtesy of PolyU)

AI-Pathologist Framework Improves Accuracy and Reliability in Cancer Diagnosis

Ensuring reliable cancer diagnosis from digital pathology remains a critical challenge as clinical decisions rely on accurate slide interpretation. While artificial intelligence (AI) has accelerated whole-slide... Read more

Industry

view channel
Image: HealthTab will distribute the Abbott Afinion 2 Analyzer to NHS-linked pharmacies for hemoglobin A1c (HbA1c) and lipid profile testing. (Photo courtesy of Abbott)

New Collaboration Expands Point-of-Care Testing Across UK Community Pharmacies

HealthTab, a wholly owned subsidiary of Avricore Health, has entered a formal collaboration agreement with Abbott to supply and distribute Abbott’s point-of-care testing products in the UK through the... Read more